A Dark Vector Cognition product

Dexcom 10-Q 2023-09-30

DXCM · CIK 1093557 · Form 10-Q · Period ended September 30, 2023 · Filed October 26, 2023

Revenue rose 26.7% to $975 million. Operating margin was 21.1%, against 19.2% a year earlier. Net income was $121 million.

8 sections, 439K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2023Quarter ended Sep 30, 2022Change
Revenue$975M$770M+26.7%
Operating income$206M$148M+39.3%
Net income$121M$101M+19.3%
Diluted EPS$0.29$0.24+20.8%
Cash and equivalents$644Mn/an/a
Operating margin*21.1%19.2%+1.9 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 48 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File Number: 000-51222

dexcom-logo-green-rgb (1).jpg

DEXCOM, INC.

(Exact name of registrant as specified in its charter)

Delaware33-0857544
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
6340 Sequence Drive, San Diego**,** CA92121
(Address of principal executive offices)(Zip Code)

(858) 200-0200

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per ShareDXCMNasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 19, 2023, there were 386,373,935 shares of the registrant’s common stock outstanding.

Table of Contents

DexCom, Inc.
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1.Financial Statements
Consolidated Balance Sheets (unaudited) as of September 30, 2023 and December 31, 20224
Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2023 and 20225
Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 30, 2023 and 20226
Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2023 and 20227
Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2023 and 20229
Notes to Consolidated Financial Statements (unaudited)11
ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations29
ITEM 3.Quantitative and Qualitative Disclosures about Market Risk40
ITEM 4.Controls and Procedures41
PART II. OTHER INFORMATION
ITEM 1.Legal Proceedings42
ITEM 1A.Risk Factors43
ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds87
ITEM 3.Defaults Upon Senior Securities87
ITEM 4.Mine Safety Disclosures87
ITEM 5.Other Information87
ITEM 6.Exhibits88
Signatures90

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Except for historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and subject to the safe harbor created by the Securities Litigation Reform Act of 1995. Such statements include declarations regarding our intent, belief, or current expectations and those of our management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks, uncertainties and other factors, some of which are beyond our control; actual results could differ materially from those indicated by such forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, but are not limited to: (i) that the information is of a preliminary nature and may be subject to further adjustment; (ii) those risks and uncertainties identified under “Risk Factors”; and (iii) the other risks detailed from time-to-time in our reports and registration statements filed with the Securities and Exchange Commission, or the SEC. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

AVAILABLE INFORMATION

Our website address is located at dexcom.com and our investor relations website is located at investors.dexcom.com. We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make available on our website, free of charge, copies of these reports and other information as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.

We announce material information to the public about us, our products, and other matters through a variety of means, including filings with the SEC, press releases, public conference calls, presentations, webcasts, and our investor relations website in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. Except as expressly set forth in this Quarterly Report on Form 10-Q, the contents of our website is not incorporated by reference into, or otherwise to be regarded as part of, this Quarterly Report on Form 10-Q or in any other report or document we file with the SEC, and any references to our website is intended to be inactive textual references only.

The information disclosed by the foregoing channels could be deemed to be material information. As such, we encourage investors, the media, and others to follow the channels listed above and review the information disclosed through such channels.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

DexCom, Inc.
Consolidated Balance Sheets
(Unaudited)
(In millions, except par value data)September 30, 2023December 31, 2022
Assets
Current assets:
Cash and cash equivalents$643.7$642.3
Short-term marketable securities2,596.61,813.9
Accounts receivable, net785.7713.3
Inventory498.6306.7
Prepaid and other current assets173.8192.6
Total current assets4,698.43,668.8
Property and equipment, net1,078.91,055.6
Operating lease right-of-use assets73.480.0
Goodwill25.325.7
Intangibles, net144.5173.3
Deferred tax assets501.3341.2
Other assets74.447.1
Total assets$6,596.2$5,391.7
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities$1,373.1$901.8
Accrued payroll and related expenses151.3134.3
Current portion of long-term senior convertible notes124.2772.6
Short-term operating lease liabilities21.020.5
Deferred revenue9.010.1
Total current liabilities1,678.61,839.3
Long-term senior convertible notes2,432.41,197.7
Long-term operating lease liabilities83.494.6
Other long-term liabilities133.9128.3
Total liabilities4,328.33,259.9
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022——
Common stock, $0.001 par value, 800.0 million shares authorized; 405.5 million and 386.4 million shares issued and outstanding, respectively, at September 30, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 20220.40.4
Additional paid-in capital3,618.02,258.1
Accumulated other comprehensive loss(35.6)(11.6)
Retained earnings765.1479.9
Treasury stock, at cost; 19.1 million shares at September 30, 2023 and 6.9 million shares at December 31, 2022(2,080.0)(595.0)
Total stockholders’ equity2,267.92,131.8
Total liabilities and stockholders’ equity$6,596.2$5,391.7

See accompanying notes

Table of Contents

DexCom, Inc.
Consolidated Statements of Operations
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
(In millions, except per share data)2023202220232022
Revenue$975.0$769.6$2,587.8$2,094.6
Cost of sales351.7275.4955.5752.8
Gross profit623.3494.21,632.31,341.8
Operating expenses:
Research and development131.4110.3369.7367.9
Amortization of intangible assets1.71.85.25.7
Selling, general and administrative284.7234.6876.6702.4
Total operating expenses417.8346.71,251.51,076.0
Operating income205.5147.5380.8265.8
Income from equity investments1.0—1.00.2
Other income (expense), net33.9(1.3)82.4(8.4)
Income before income taxes240.4146.2464.2257.6
Income tax expense119.745.0179.08.2
Net income$120.7$101.2$285.2$249.4
Basic net income per share$0.31$0.26$0.74$0.64
Shares used to compute basic net income per share386.6389.8386.7390.4
Diluted net income per share$0.29$0.24$0.69$0.60
Shares used to compute diluted net income per share426.8425.8428.3428.0

See accompanying notes

Table of Contents

DexCom, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
(In millions)2023202220232022
Net income$120.7$101.2$285.2$249.4
Other comprehensive income (loss), net of tax:
Translation adjustments and other(7.0)(19.6)(25.8)(34.9)
Unrealized gain (loss) on marketable debt securities0.71.51.8(6.7)
Total o

Showing the first 8K of 116K characters. Open the full section

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview
Who We Are
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in 2018 and more recently received marketing clearance from the FDA on the Dexcom G7®, or G7, in December 2022. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries.
Global Presence
We have built a direct sales organization in North America and certain international markets to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in North America and several international markets that allow distributors to sell our products.
Future Developments
Product Development: We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior.
Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems.
New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring.
Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting estimates during the nine months ended September 30, 2023.

Table of Contents

Overview of Financial Results
The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow.
Key Highlights for the Three Months Ended September 30, 2023 include the following:
RevenueGross ProfitOperating IncomeNet IncomeOperating Cash Flow
$975.0 million$623.3 million$205.5 million$120.7 million$269.2 million
up 27% from the same period 2022up 26% from the same period 2022up 39% from the same period 2022up 19% from the same period 2022down 8% from the same period 2022

We ended the third quarter of 2023 with cash, cash equivalents and short-term marketable securities totaling $3.24 billion.

Business Trends

Looking ahead we expect our business could be affected by the following:

  • Increase in the worldwide incidence of people diagnosed with diabetes and costs related to the management and treatment of diabetes.

  • Changes in medical reimbursement policies and programs.

  • Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs.

  • An expected interest in empowering consumers to make better-informed decisions about their own health and new potential options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional health care settings.

  • Growing research and interest in the use of CGM technology outside of the ambulatory care setting, including use by hospital systems.

  • Continued product innovation and competition from other CGM device makers.

  • Our ability to scale efficiently with our Malaysia manufacturing facility.

Table of Contents

Results of Operations

6

Financial Overview
Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022
Three Months Ended September 30,2023 - 2022
(In millions, except per share amounts)2023% of Revenue (1)2022% of Revenue (1)$ Change% Change
Revenue$975.0100%$769.6100%$205.427%
Cost of sales351.736%275.436%76.328%
Gross profit623.363.9%494.264.2%129.126%
Operating expenses:
Research and development131.413%110.314%21.119%
Amortization of intangible assets1.7—%1.8—%(0.1)(6)%
Selling, general and administrative284.729%234.630%50.121%
Total operating expenses417.843%346.745%71.121%
Operating income205.521%147.519%58.039%
Income from equity investments1.0—%——%1.0**
Other income (expense), net33.93%(1.3)—%35.2**
Income before income taxes240.425%146.219%94.264%
Income tax expense119.712%45.06%74.7**
Net income$120.712%$101.213%$19.519%
Basic net income per share$0.31**$0.26**$0.0519%
Diluted net income per share$0.29**$0.24**$0.0521%
(1) The sum of the individual percentages may not equal the total due to rounding.
** Not meaningful

Table of Contents

Revenue

We expect that the revenue we generate from the sales of our products will fluctuate from quarter to quarter. We typically experience seasonality, with lower sales in the first quarter of each year compared to the immediately preceding fourth quarter. This seasonal sales pattern relates to U.S. annual insurance deductible resets and unfunded flexible spending accounts.

Cost of sales

Cost of sales includes direct labor and materials costs related to each product sold or produced, including assembly, test labor and scrap, as well as factory overhead supporting our manufacturing operations. Factory overhead includes facilities, material procurement and control, manufacturing engineering, quality assurance, supervision and management. These costs are primarily salary, fringe benefits, share-based compensation, facility expense, supplies and purchased services. All of our manufacturing costs are included in cost of sales. In addition, amortization of certain licensing related intangibles are also included in cost of sales.

Research and development

Our research and development expenses primarily consist of engineering and research expenses related to our continuous glucose monitoring technology, clinical trials, regulatory expenses, quality assurance programs, materials and products for clinical trials. Research and development expenses are primarily related to employee compensation, including salary, fringe benefits, share-based compensation, and temporary employee expenses. We also incur significant expenses to operate our clinical trials including budgeted clinical site compensation and reimbursement, study monitoring and oversight expenses, clinical trial product and associated travel expenses. Our research and development expenses also include fees for design services, contractors and development materials.

Amortization of intangible assets

Our amortization expense primarily relates to acquired technology and intellectual property and other acquired intangible assets.

Selling, general and administrative

Our selling, general and administrative expenses primarily consist of salary, fringe benefits and share-based compensation for our executive, financial, sales, marketing, information technology and administrative functions. Other significant expenses include commissions, marketing and advertising, IT software license costs, insurance, professional fees for our outside legal counsel and independent auditors, litigation expenses, patent application expenses and consulting expenses.

Income from equity investments

Income from equity investments is comprised of realized gains from the sale of an equity investment.

Other income (expense), net

Other income (expense), net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses due to the effects of foreign currency fluctuations, and interest expense related to our senior convertible notes.

Table of Contents

Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022
RevenueThe revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base and the shift to G7, partially offset by mix shift and price associated with the evolution of our channel and product strategy. Disposable sensor and other revenue comprised approximately 90% of total revenue and Reusable Hardware revenue comprised approximately 10% of total revenue for the three months ended September 30, 2023. Disposable sensor and other revenue comprised approximately 87% of total revenue and Reusable Hardware revenue comprised approximately 13% of total revenue for the three months ended September 30, 2022.
Cost of sales & Gross profitCost of sales and gross profit increased primarily due to an increase in sales volume. The decrease in gross profit margin percentage in the third quarter of 2023 compared to the third quarter of 2022 was primarily driven by the amortization of an intangible asset and price, product, and channel mix changes.
Research and development expenseResearch and development expense increased primarily due to $13.6 million in compensation-related costs most notably due to higher headcount. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.
Selling, general and administrative expenseSelling, general and administrative expense increased primarily due to $32.2 million in compensation-related costs most notably due to higher headcount and $12.6 million in legal expense primarily related to a patent infringement lawsuit.
Other income (expense), netOther income (expense), net, increased primarily due to $35.8 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a significant increase in market interest rates, as well as an increase in the average invested balances compared to the same period in 2022.
Income tax expenseOur estimated annual effective tax rate from normal, recurring operations decreased from 28.5% to 24.7% during the three months ended September 30, 2023 primarily due to decrease in state and foreign taxes, increase in federal tax credits generated, partially offset by an increase to unrecognized tax benefits and an increase in disallowed executive compensation. There are discrete taxes related to the intra-entity transfer of certain intellectual property and decrease in the state tax rate applied to beginning of year deferred tax assets. The income tax expense recorded for the three months ended September 30, 2022 was primarily attributable to income tax expense from normal, recurring operations.

Table of Contents

4

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022
Nine Months Ended September 30,2023 - 2022
(In millions, except per share amounts)2023% of Revenue (1)2022% of Revenue (1)$ Change% Change
Revenue$2,587.8100%$2,094.6100%$493.224%
Cost of sales955.537%752.836%202.727%
Gross profit1,632.363.1%1,341.864.1%290.522%
Operating expenses:
Research and development369.714%367.918%1.8—%
Amortization of intangible assets5.2—%5.7—%(0.5)(9)%
Selling, general and administrative876.634%702.434%174.225%
Total operating expenses1,251.548%1,076.051%175.516%
Operating income380.815%265.813%115.043%
Income from equity investments1.0—%0.2—%0.8**
Other income (expense), net82.43%(8.4)—%90.8**
Income before income taxes464.218%257.612%206.680%
Income tax expense179.07%8.2—%170.8**
Net income$285.211%$249.412%$35.814%
Basic net income per share$0.74**$0.64**$0.1016%
Diluted net income per share$0.69**$0.60**$0.0915%
(1) The sum of the individual percentages may not equal the total due to rounding.
** Not meaningful

Table of Contents

Nine Months Ended September 30, 2023 Compared to Nine Months Ended September 30, 2022
RevenueThe revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base and the shift to G7, partially offset by mix shift and price associated with the evolution of our channel and product strategy. Disposable sensor and other revenue comprised approximately 89% of total revenue and Reusable Hardware revenue comprised approximately 11% of total revenue for the nine months ended September 30, 2023. Disposable sensor and other revenue comprised approximately 86% of total revenue and Reusable Hardware revenue comprised approximately 14% of total revenue for the nine months ended September 30, 2022.
Cost of sales & Gross profitCost of sales and gross profit increased primarily due to an increase in sales volume. The decrease in gross profit margin percentage in 2023 compared to 2022 was primarily driven by the amortization of an intangible asset and price, product, and channel mix changes.
Research and development expenseResearch and development expense increased primarily due to $26.8 million in compensation-related costs most notably due to higher headcount and various increases to individually insignificant items, partially offset by $16.4 million of lower third party and consulting fees primarily related to software development for new products and significant enhancements and $11.5 million in lower costs related to set-up and validation costs for new CGM equipment. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy.
Selling, general and administrative expenseSelling, general and administrative expense increased primarily due to $73.9 million in compensation-related costs most notably due to higher headcount, $43.0 million in legal expense primarily related to a patent infringement lawsuit, and $30.7 million in advertising and marketing costs associated with global product launches.
Other income (expense), netOther income (expense), net, increased primarily due to $90.8 million in interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The increase in interest income was related to a significant increase in market interest rates, as well as an increase in the average invested balances compared to the same period in 2022.
Income tax expenseThe income tax expense recorded for the nine months ended September 30, 2023 is primarily attributable to state and foreign income taxes, nondeductible executive compensation, increases to unrecognized tax benefits, and impact of foreign operations, partially offset by federal tax credits generated. There are discrete taxes related to the intra-entity asset transfer of certain intellectual property, and decrease in the state tax rate applied to beginning of year deferred tax assets, partially offset by excess tax benefits recognized for share-based compensation for employees, net of disallowed executive compensation. The income tax expense recorded for the nine months ended September 30, 2022 is primarily attributable to income tax expense from normal, recurring operations, partially offset by excess tax benefits recognized for share-based compensation for employees (net of disallowed executive compensation) and the Verily milestone payment, and generation of research and development tax credits.

Table of Contents

Liquidity and Capital Resources
Overview, Capital Resources, and Capital Requirements

Our principal sources of liquidity are our existing cash, cash equivalents and marketable securities, cash generated from operations, proceeds from our senior convertible notes issuances, and access to our Credit Facility. Our primary uses of cash have been for research and development programs, selling and marketing activities, capital expenditures, acquisitions of businesses, and debt service costs.

We expect that cash provided by our operations may fluctuate in future periods as a result of a number of factors, including fluctuations in our operating results, working capital requirements and capital deployment decisions. We have historically invested our cash primarily in U.S. dollar-denominated, investment grade, highly liquid obligations of U.S. government agencies, commercial paper, corporate debt, and money market funds. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.

Our future capital requirements will depend on many factors, including but not limited to:

The evolution of the international expansion of our business and the revenue generated by sales of our approved products and other future products;Our ability to efficiently scale our operations to meet demand for our current and any future products;The success of our research and development efforts;
The expenses we incur in manufacturing, developing, selling and marketing our products;The costs, timing and risks of delays of additional regulatory approvals;The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
The quality levels of our products and services;The emergence of competing or complementary technological developments;The terms and timing of any collaborative, licensing and other arrangements that we may establish; and
The third-party reimbursement of our products for our customers;The rate of progress and cost of our clinical trials and other development activities;The acquisition of businesses, products and technologies and our ability to integrate and manage any acquired businesses, products and technologies.

We expect that existing cash and short-term investments and cash flows from our future operations will generally be sufficient to fund our ongoing core business. As current borrowing sources become due, we may be required to access the capital markets for additional funding. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. In the event that we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market in light of those earning levels.

A substantial portion of our operations are located in the United States, and the majority of our sales since inception have been made in U.S. dollars. We will be exposed to additional foreign currency exchange risk related to our international operations as we expand our manufacturing internationally and as our business continues to increase in international markets. See “Foreign Currency Exchange Risk” in Part II, Item 7A of our Annual Report for more information.

Table of Contents

Main Sources of Liquidity

Cash, cash equivalents and short-term marketable securities

Our cash, cash equivalents and short-term marketable securities totaled $3.24 billion as of September 30, 2023. None of those funds were restricted and $3.07 billion (approximately 95%) of those funds were located in the United States.

Cash flow from Operations

For the nine months ended September 30, 2023, we had positive cash flows of $614.9 million from operating activities. We anticipate that we will continue to generate positive cash flows from operations for the foreseeable future.

Senior Convertible Notes

We received net proceeds of $836.6 million in November 2018 from the 2023 Notes offering, net proceeds of $1.19 billion in May 2020 from the 2025 Notes offering, and net proceeds of $1.23 billion from the 2028 Notes offering. We used $100.0 million of the net proceeds from the offering of the 2023 Notes to repurchase a portion of our common stock in 2018. We used $282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022. We used $289.9 million of the net proceeds from the offering of the 2028 Notes to purchase capped call transactions and repurchase shares of our common stock in May 2023. We intend to use the remainder of the net proceeds from the 2023 Notes, 2025 Notes, and 2028 Notes offerings for general corporate purposes and capital expenditures, including working capital needs. We may also use the net proceeds to expand our current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, we do not have any significant commitments with respect to any such acquisitions or investments at this time.

In connection with the 2023 Notes and 2028 Notes offerings, we purchased the 2023 Note Hedge and 2028 Capped Calls, respectively. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for conversion activity related to the 2023 Notes and shares received as the result of exercising a portion of the 2023 Note Hedge as well as for more information about our senior convertible notes, the 2023 Note Hedge, the 2023 Warrants, and the 2028 Capped Calls.

Revolving Credit Agreement

As of September 30, 2023, we had no outstanding borrowings, $7.3 million in outstanding letters of credit, and a total available balance of $192.7 million under the Amended Credit Agreement. We monitor counterparty risk associated with the institutional lenders that are providing the Credit Facility. We currently believe that the Credit Facility will be available to us should we choose to borrow under it. Revolving loans will be available for general corporate purposes, including working capital and capital expenditures. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for more details on the Revolving Credit Agreement.

Short-term Liquidity Requirements

Our short-term liquidity requirements primarily consist of regular operating costs, interest payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and short-term material cash requirements as described below. As of September 30, 2023, we had a working capital ratio of 2.80 and a quick ratio of 2.40, which indicates that our current assets are more than enough to cover our short-term liabilities. We expect to have significant capital expenditures for the next year to drive our strategic initiative of building out our manufacturing facilities and/or equipment in Malaysia and Ireland and the capacity scale-up in Mesa, Arizona.

We believe that our cash, cash equivalents, and marketable securities balances, projected cash contributions from our commercial operations, and borrowings under our Credit Facility will be sufficient to meet our anticipated seasonal working capital needs, all capital expenditure requirements, material cash requirements as described below, and other liquidity requirements associated with our operations for at least the next 12 months. We may use cash for strategic initiatives that strengthen our foundation for long-term growth.

The outstanding principal related to our 2023 Notes of $124.3 million as of September 30, 2023 and any amount in excess of the principal amount will primarily settle through a combination of cash and stock on or before the maturity date of December 1, 2023.

Table of Contents

Long-term Liquidity Requirements

Our long-term liquidity requirements primarily consist of interest and principal payments related to our senior convertible notes, capital expenditures for the development of our manufacturing facilities and office spaces, and long-term material cash requirements as described below. As of September 30, 2023, we had a debt-to-assets ratio of 0.39, which indicates that our total assets are more than enough to cover our short-term and long-term debts. As demand grows for our products, we will continue to expand global operations to meet demand through investments in manufacturing and operations. We expect to meet our long-term liquidity requirements from our main sources of liquidity as described above to support our future operations, capital expenditures, acquisitions, and other liquidity requirements associated with our operations beyond the next 12 months.

As of September 30, 2023, we have outstanding senior convertible notes that will mature in November 2025 and May 2028. However, the outstanding principal of our senior convertible notes could be converted into cash and/or shares of our common stock prior to maturity once certain conditions are met. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for information on conversion rights prior to maturity.

Material Cash Requirements

From time to time in the ordinary course of business, we enter into a variety of purchase arrangements including but not limited to, purchase arrangements related to capital expenditures, components used in manufacturing for the United States and Malaysia, and research and development activities. See “Contractual Obligations” below in Part I, Item 2 of this Quarterly Report for more information.

We issued senior convertible notes in November 2018, May 2020, and May 2023. These obligations include both principal and interest for these notes. Although these notes mature in December 2023, November 2025, and May 2028, respectively, they may be converted into cash and/or shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayment of the principal amounts sooner than the scheduled repayment. As of September 30, 2023, we had outstanding letters of credit of $7.3 million for which we cannot forecast with certainty the amount and timing of repayments. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for further discussion of the terms of our senior convertible notes.

We are party to various leasing arrangements, primarily for office, manufacturing and warehouse space that expire at various times through December 2030, excluding any renewal options. We also have land leases in Penang, Malaysia for the build-out of our international manufacturing facility lease that expire through 2082. We anticipate incurring significant expenditures related to the build-out of the Malaysia manufacturing facility and equipment over the next year and the build-out of the Ireland manufacturing facility and equipment over the next five years. See Note 6 “Leases and Other Commitments” to the consolidated financial statements in Part II, Item 8 of our Annual Report for more information about our leases.

See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for more information about the terms of the Credit Agreement, our senior convertible notes, the 2023 Note Hedge, the 2023 Warrants, and the 2028 Capped Calls.

Table of Contents

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report for complete consolidated statements of cash flows for these periods.

9887

As of September 30, 2023, we had $3.24 billion in cash, cash equivalents and short-term marketable securities, which is an increase of $784.1 million compared to $2.46 billion as of December 31, 2022.

The primary cash flows during the nine months ended September 30, 2023 and September 30, 2022 are described below. See the consolidated financial statements in Part I, Item 1 of this Quarterly Report for complete consolidated statements of cash flows for these periods.

Table of Contents

Nine Months Ended
September 30, 2023September 30, 2022
Operating Cash Flows+$285.2 million of net income, $68.4 million of net non-cash adjustments, and a net increase of $261.3 million in changes of working capital balances+$249.4 million of net income and $194.9 million of net non-cash adjustments, and a net increase of $92.7 million in changes of working capital balances
Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization.Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization.
Investing Cash Flows-$719.5 million in net purchases of marketable securities-$301.3 million in capital expenditures
-$184.1 million in capital expenditures-$12.5 million in purchases of equity investments
-19.5 million in purchases of equity investments-$9.9 million in net purchases of marketable securities
-$3.9 million in acquisitions, net of cash acquired
Financing Cash Flows+$1.23 billion in proceeds from issuance of senior convertible notes, net of issuance costs+$22.5 million in proceeds from issuance of common stock under our employee stock plans
+$26.6 million in proceeds from issuance of common stock under our employee stock plans-$557.7 million in purchases of treasury stock
-$650.5 million in payments for conversions of senior convertible notes-$14.6 million in payments for financing leases
-$188.7 million in purchases of treasury stock
-$101.3 million in purchases of capped call transactions
Contractual Obligations

We presented our contractual obligations as of December 31, 2022 in Note 6 “Leases and Other Commitments” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There were no significant changes to our lease obligations during the nine months ended September 30, 2023. As of September 30, 2023, we had approximately $420.3 million of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year. See Note 5 “Debt” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report for conversion activity related to our senior convertible notes.

Recent Accounting Guidance

For a description of recently issued accounting pronouncements and the potential impact on our consolidated financial statements, if any, see Note 1 “Organization and Significant Accounting Policies” to the consolidated financial statements in Part I, Item 1 of this Quarterly Report.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There were no material changes to our quantitative and qualitative disclosures about market risk during the nine months ended September 30, 2023. See Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 for a detailed discussion of our market risks.

Table of Contents

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Regulations under the Exchange Act require public companies to maintain “disclosure controls and procedures,” which are defined to mean a company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act, is accumulated and timely communicated to management, including our Chief Executive Officer and Chief Financial Officer, recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation as of the end of the period covered by this report of the effectiveness of our disclosure controls and procedures. Based on their evaluation as of September 30, 2023, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date for this purpose.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Limitation on Effectiveness of Controls

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, we cannot guarantee that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

Table of Contents

PART II. OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS

We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.

Between June 2021 through the nine months ended September 30, 2023, we and certain Abbott Diabetes Care, Inc. (“Abbott”) entities have served complaints against each other in multiple jurisdictions, including in the United States (United States District Court ("U.S.D.C.”), District of Delaware), the United Kingdom (Business and Property Courts of England and Wales), France (United Patent Court (“UPC”) in Paris), Spain (Commercial Courts of Barcelona) and Germany (National Courts (“N.C.”) of Munich, Mannheim, Dusseldorf and Hamburg and the UPC in Munich), primarily involving claims of patent infringement, invalidity and other patent related actions. In June and July of 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (N.C. in Mannheim) and filed additional patent infringement actions in May 2023 in Germany (N.C. in Munich) over certain of Abbott's continuous glucose monitoring products. In July and August 2023, we initiated patent infringement litigation in France and Germany in the UPC and in Spain (Commercial Courts of Barcelona).

Between July 2021 through the nine months ended September 30, 2023, Abbott initiated patent infringement litigation against Dexcom in multiple jurisdictions, including the United States (U.S.D.C., Delaware), the United Kingdom (Business and Property Courts of England and Wales), and in Germany (N.C. in Mannheim, Dusseldorf and Hamburg) over certain of Dexcom's continuous glucose monitoring products. In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction. Three trials on liability have already been conducted in the United Kingdom. On October 18, judgment was handed down in favor of Dexcom in one of these trials. The parties are awaiting rulings on the remaining two. Dexcom and Abbott seek injunctive relief and monetary damages as a result of their respective claims.

In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the U.S.D.C., District of Delaware alleging that Dexcom breached the parties' Settlement and License Agreement dated July 2, 2014 (“SLA”). The U.S.D.C., District of Delaware consolidated Abbott’s breach of contract lawsuit with Dexcom’s patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas. Dexcom asserted counterclaims that Abbott also breached the SLA. A jury trial on Abbott’s breach of contract claims commenced on July 10, 2023. On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims. Dexcom’s patent infringement claims in Delaware are stayed until November 10, 2023, at which point the U.S. Patent and Trademark Office will have issued its final written decisions on certain patents involved in the lawsuit. We will continue to enforce the remaining claims of the patents asserted in Delaware.

Abbott’s patent infringement action against Dexcom is currently scheduled for trial in the U.S.D.C., District of Delaware on March 11, 2024. In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott’s patents and Abbott dropped four other patents from the litigation.

Commencing in December 2023, Abbott has several patent infringement hearings against Dexcom in the National Court in Hamburg and Munich wherein Abbott is seeking damages and injunctive relief. In March and April of 2024, Dexcom has several patent infringement hearings in Munich against Abbott, wherein Dexcom is seeking damages and injunctive relief.

Due to uncertainty surrounding patent litigation procedures initiated by Dexcom and Abbott throughout multiple jurisdictions, we are unable to reasonably estimate the ultimate outcome of any of the litigation matters at this time. We intend to protect our intellectual property and defend against Abbott’s claims vigorously in all of these actions.

We do not believe we are party to any other currently pending legal proceedings, the outcome of which could have a material adverse effect on our business, financial condition, or results of operations. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial condition, or results of operations.

Table of Contents

Item 1A. RISK FACTORS

Our short and long-term success is subject to numerous risks and uncertainties, many of which involve factors that are difficult to predict or beyond our control. Before making a decision to invest in, hold or sell our common stock, stockholders and potential stockholders should carefully consider the risks and uncertainties described below, in addition to the other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q, as well as the other information we file with the SEC. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that case, the value of our common stock could decline and stockholders may lose all or part of their investment. Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business, financial condition or results of operations. Refer to our disclaimer regarding forward-looking statements at the beginning of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part I, Item 2 of this Quarterly Report.

Summary of Risk Factors

The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities. As a result, the below summary risks do not contain all of the information that may be important to you, and you should read the summary risks together with the more detailed discussion of risks set forth following this section under the heading “Risk Factors,” as well as elsewhere in this Quarterly Report on Form 10-Q. Additional risks, beyond those summarized below or discussed elsewhere in this Quarterly Report on Form 10-Q, may apply to our activities or operations as currently conducted or as we may conduct them in the future or in the markets in which we operate or may in the future operate. Consistent with the foregoing, we are exposed to a variety of risks, including risks associated with the following:

  • If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.

  • We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.

  • Although many third-party payors have adopted some form of coverage policy for continuous glucose monitoring devices, our products do not always have such coverage, including simple broad-based contractual coverage with third-party payors, and we frequently experience administrative challenges in obtaining coverage or reimbursement for our products. If we are unable to obtain adequately broad coverage or reimbursement for our products or any future products from third-party payors, our revenue may be negatively impacted.

  • The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.

  • Our products may not achieve or maintain market acceptance.

  • If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.

  • Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.

  • We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.

  • If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.

  • We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.

  • We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.

  • We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.

  • We have incurred significant losses in the past and may incur losses in the future.

Table of Contents

  • We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.

  • Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.

  • We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.

  • Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.

  • Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.

  • If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.

  • We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.

  • Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.

  • We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.

  • We could become the subject of governmental investigations, claims and litigation.

  • Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substa

Showing the first 8K of 237K characters. Open the full section

Item 5. OTHER INFORMATION

Trading Plans

During the three months ended September 30, 2023, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:

Character of Trading Arrangement
NameTitleActionAction DateRule 10b5-1*Non-Rule 10b5-1**Total Shares to be SoldExpiration Date**(1)**
Michael BrownExecutive Vice President, Chief Legal OfficerTermination(2)8/29/2023X3,61212/15/2023
Michael BrownExecutive Vice President, Chief Legal OfficerAdoption(2)8/29/2023XUp to 14,463(3)8/30/2024
Nicholas AugustinosDirectorAdoption9/15/2023XUp to 7,6489/15/2024
* Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.
(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on 12/15/2022 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect, under the Exchange Act.
(3) The number of shares of common stock sold under the Rule 10b5-1 trading arrangement will be net of shares withheld for applicable tax obligations upon the vesting of covered securities and is not yet determinable.

Each new Rule 10b5-1 Plan that was adopted in the above table includes a representation from Messrs. Brown and Augustinos, respectively, to the broker administering the plan that he was not in possession of any material nonpublic information regarding Dexcom or the securities subject to the Rule 10b5-1 Plan at the time the Rule 10b5-1 Plan was entered into. A similar representation was made to Dexcom in connection with the adoption of the Rule 10b5-1 Plan under Dexcom’s insider trading policy. Those representations were made as of the Adoption Date set forth above, and speak only as of that date. In making those representations, there is no assurance with respect to any material nonpublic information of which the directors and officers was unaware, or with respect to any material nonpublic information acquired by the above directors and officers or Dexcom after the date of the representation.

Once executed, transactions under a Rule 10b5-1 Plan adopted during the period described above will be disclosed publicly through Form 4 and/or Form 144 filings with the SEC in accordance with applicable securities laws, rules, and regulations. Except as may be required by law, Dexcom does not undertake any obligation to update or report any modification, termination, or other activity under current or future Rule 10b5-1 plans that may be adopted by Messrs. Brown and Augustinos, respectively, or other officers or directors of Dexcom.

Table of Contents

Item 6. EXHIBITS

Incorporated by Reference
Exhibit NumberExhibit DescriptionFormFile No.Date of First FilingExhibit NumberProvided Herewith
10.01*Amendment Number Sixteen to Amended and Restated Non-Exclusive Distribution Agreement, dated September 1, 2023, by and between DexCom, Inc. and Byram Healthcare Centers, Inc.————X
10.02*Amendment Number Thirteen to Non-Exclusive Distribution Agreement, dated September 1, 2023, by and between DexCom, Inc. and RGH Enterprises, LLC.————X
31.01Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).————X
31.02Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a).————X
32.01**Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).————X
32.02**Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule 13a-14(b).————X
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX

Table of Contents

Incorporated by Reference
Exhibit NumberExhibit DescriptionFormFile No.Date of First FilingExhibit NumberProvided Herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 is formatted in Inline XBRLX
*Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
**This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that Dexcom specifically incorporates it by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DEXCOM, INC. (Registrant)
Dated:October 26, 2023By:/s/ KEVIN R. SAYER
Kevin R. Sayer, Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer)
Dated:October 26, 2023By:/s/ JEREME M. SYLVAIN
Jereme M. Sylvain, Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)